Literature DB >> 12871537

An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13.

D J Bowen1.   

Abstract

The susceptibility of von Willebrand factor (VWF) of blood group O, A, B and AB to proteolysis by the ADAMTS13 metalloprotease was investigated. Multimeric analysis indicated that the rate of VWF proteolysis differed between blood groups and was greater for group O VWF than for non-O VWF in the rank order O >/= B > A >/= AB. Measurement of the collagen binding activity of VWF of each blood group following proteolysis for a fixed time interval corroborated the results obtained on multimer analysis: the loss of collagen binding activity was greater for VWF of group O compared with non-O VWF, in the rank order O >/= B > A >/= AB. Ristocetin was found to increase the rate of VWF proteolysis approximately two-fold; the differential between blood groups was retained in the presence of ristocetin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871537     DOI: 10.1046/j.1538-7836.2003.00007.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  44 in total

1.  Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Authors:  V H Flood; J C Gill; P A Christopherson; J S Wren; K D Friedman; S L Haberichter; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

Review 2.  Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells.

Authors:  Melissa M Lee-Sundlov; Sean R Stowell; Karin M Hoffmeister
Journal:  J Thromb Haemost       Date:  2020-05-28       Impact factor: 5.824

3.  Investigating the influence of age, gender and ABO blood group on ADAMTS-13 antigen and activity levels in healthy Arabs.

Authors:  Anwar M Al-Awadhi; Seham K Al-Sharrah; Mehrez M Jadaon; Faisal Al-Sayegh
Journal:  Blood Transfus       Date:  2013-12-04       Impact factor: 3.443

4.  ABO blood type A is associated with increased risk of ARDS in whites following both major trauma and severe sepsis.

Authors:  John P Reilly; Nuala J Meyer; Michael G S Shashaty; Rui Feng; Paul N Lanken; Robert Gallop; Sandra Kaplan; Maximilian Herlim; Nathaniel L Oz; Isabel Hiciano; Ana Campbell; Daniel N Holena; Muredach P Reilly; Jason D Christie
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

Review 5.  ABO Blood Group as a Model for Platelet Glycan Modification in Arterial Thrombosis.

Authors:  Ming Zhong; Hanrui Zhang; John P Reilly; Jason D Chrisitie; Mayumi Ishihara; Tadahiro Kumagai; Parastoo Azadi; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

6.  ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?

Authors:  Natália Mastantuono Nascimento; Sergio Paulo Bydlowski; Rosangela Paula Silva Soares; Danieli Castro Oliveira de Andrade; Eloísa Bonfá; Luciana Parente Costa Seguro; Eduardo Ferreira Borba
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

7.  Indian Bombay phenotype: it is different!

Authors:  Bipin Kulkarni; Ajit Gorakshakar; Vimala Singh; Anita Parihar; Ajay Donta; Harita Gogri; Seema Jadhav; Kanjaksha Ghosh; Shrimati Shetty
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

8.  Aberrant expression of histo-blood group A type 3 antigens in vascular endothelial cells in inflammatory sites.

Authors:  Mizuho Nosaka; Yuko Ishida; Aki Tanaka; Takahito Hayashi; Tomoko Miyashita; Chikako Kaminaka; Wolfgang Eisenmenger; Fukumi Furukawa; Akihiko Kimura
Journal:  J Histochem Cytochem       Date:  2007-11-12       Impact factor: 2.479

9.  The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Authors:  Natalia Rydz; Laura L Swystun; Colleen Notley; Andrew D Paterson; J Jacob Riches; Kate Sponagle; Boonchai Boonyawat; Robert R Montgomery; Paula D James; David Lillicrap
Journal:  Blood       Date:  2013-03-25       Impact factor: 22.113

Review 10.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.